Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist
- PMID: 27150869
- DOI: 10.2169/internalmedicine.55.4418
Treatment of Mitochondrial Diabetes with a Peroxisome Proliferator-activated Receptor (PPAR)-gamma Agonist
Abstract
The 3243 A>G mutation in mitochondrial DNA is the most common cause of monogenic diabetes mellitus in Japan. A 45-year-old woman with mitochondrial diabetes and significant insulin resistance presented with hypoadiponectinemia despite a normal amount of visceral fat. Three months of treatment with pioglitazone (PIO) improved her blood glucose profile and response to the 75-g oral glucose tolerance test. These changes were accompanied by the amelioration of her insulin resistance and the impairment of early-phase insulin secretion. Her serum adiponectin levels increased to the normal range. In this case of mitochondrial diabetes, PIO was effective for glycemic control.
Comment in
-
Diabetes due to Mitochondrial Adipopathy.Intern Med. 2017;56(6):745. doi: 10.2169/internalmedicine.56.7950. Epub 2017 Mar 17. Intern Med. 2017. PMID: 28321084 Free PMC article. No abstract available.
-
Diabetes due to Mitochondrial Adipopathy.Intern Med. 2017;56(6):747. doi: 10.2169/internalmedicine.56.7750. Epub 2017 Mar 17. Intern Med. 2017. PMID: 28321085 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
